Evidence map›Paper›PMID 36388948›Full record

ArticleFrontiers in medicine2022

Synergistic effect of myocardial injury and mid-regional proAdrenomedullin elevation in determining clinical outcomes of SARS-CoV-2 patients.

Silvia Spoto, Fabio Mangiacapra, Giorgio D'Avanzo, Daniela Lemme, César Bustos Guillén, Antonio Abbate, John Daniel Markley, Federica Sambuco, Roshanak Markley, Marta Fogolari and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 3 countries.

Silvia SpotoDepartment of Diagnostic and Therapeutic Medicine, University Campus Bio-Medico of Rome, Rome, Italy.
Fabio MangiacapraUnit of Cardiovascular Science, University Campus Bio-Medico of Rome, Rome, Italy.
Giorgio D'AvanzoDepartment of Diagnostic and Therapeutic Medicine, University Campus Bio-Medico of Rome, Rome, Italy.
Daniela LemmeDepartment of Diagnostic and Therapeutic Medicine, University Campus Bio-Medico of Rome, Rome, Italy.
César Bustos GuillénDivision of Infectious Diseases, Department of Internal Medicine, Clinica Universidad de los Andes, Santiago Metropolitan, Chile.
Antonio AbbateDivision of Cardiology, Department of Internal Medicine, Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, United States.
John Daniel MarkleyDivision of Infectious Disease and Epidemiology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, United States.
Federica SambucoDepartment of Emergency, University Campus Bio-Medico of Rome, Rome, Italy.
Roshanak MarkleyDivision of Cardiology, Department of Internal Medicine, Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, United States.
Marta FogolariUnit of Clinical Laboratory Science, University Campus Bio-Medico of Rome, Rome, Italy.
Luciana LocorriereDepartment of Diagnostic and Therapeutic Medicine, University Campus Bio-Medico of Rome, Rome, Italy.
Domenica Marika LupoiDepartment of Diagnostic and Therapeutic Medicine, University Campus Bio-Medico of Rome, Rome, Italy.
Giulia BattifogliaDepartment of Diagnostic and Therapeutic Medicine, University Campus Bio-Medico of Rome, Rome, Italy.
Sebastiano CostantinoDepartment of Diagnostic and Therapeutic Medicine, University Campus Bio-Medico of Rome, Rome, Italy.
Massimo CiccozziUnit of Medical Statistics and Molecular Epidemiology, University Campus Bio-Medico of Rome, Rome, Italy.
Silvia AngelettiUnit of Clinical Laboratory Science, University Campus Bio-Medico of Rome, Rome, Italy.
Università Campus Bio-Medico · ITCampus Bio Medico University Hospital · ITVirginia Commonwealth University · USUnited States Department of Veterans Affairs · USUniversidad de Los Andes, Chile · CL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Coronavirus disease 2019 (COVID-19) is a systemic disease induced by SARS-CoV-2 causing myocardial injury. To date, there are few data on the correlation between mid-regional proAdrenomedullin (MR-proADM) and myocardial injury. The aim of this study was to evaluate whether the association of myocardial injury and elevated mid-regional proAdrenomedullin values could predict mortality of SARS-CoV-2 patients, to offer the best management to COVID-19 patients. Materials and methods: All patients hospitalized for SARS-CoV-2 infection at the COVID-19 Center of the Campus Bio-Medico of Rome University were included between October 2020 and March 2021 and were retrospectively analyzed. Myocardial injury was defined as rising and/or fall of cardiac hs Troponin I values with at least one value above the 99th percentile of the upper reference limit (≥15.6 ng/L in women and ≥34.2 ng/L in men). The primary outcome was 30-day mortality. Secondary outcomes were the comparison of MR-proADM, CRP, ferritin, and PCT as diagnostic and prognostic biomarkers of myocardial injury. Additionally, we analyzed the development of ARDS, the need for ICU transfer, and length of stay (LOS). Results: A total of 161 patients were included in this study. Of these, 58 (36.0%) presented myocardial injury at admission. An MR-proADM value ≥ 1.19 nmol/L was defined as the optimal cut-off to identify patients with myocardial injury (sensitivity 81.0% and specificity 73.5%). A total of 121 patients (75.2%) developed ARDS, which was significantly more frequent among patients with myocardial injury (86.2 vs. 68.9%, Conclusion: The study is focused on the correlation between myocardial injury and MR-proADM. Myocardial injury induced by SARS-CoV-2 is strongly associated with high MR-proADM values and mortality.

Indexed as

COVID-19mid-regional proAdrenomedullinmyocardial injurySARS-CoV-2Troponin I (tni)

Identifiers

PMID36388948
PMCPMC9643355
OpenAlexW4307250546

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.